The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Editorial
PreviousPrevious
Volume 334:529-530 February 22, 1996 Number 8
NextNext

Management of Myeloma with Bisphosphonates

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
Osteolytic lesions are a hallmark of multiple myeloma. At the time of diagnosis, most patients have bone lesions whose extent is directly related to the mass of the tumor. About 30 percent of patients also have hypercalcemia. Bone lesions and hypercalcemia are major causes of morbidity in these patients, causing asthenia, cachexia, bone pain, fractures, compression of the spinal cord, and renal insufficiency. Thus, the diagnosis and treatment of bone disease are essential to the care of patients with multiple myeloma.

Unfortunately, the efficacy of treatment of the skeletal effects of multiple myeloma is very limited. Only patients who have . . . [Full Text of this Article]

References


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.